Drug Intelligence Bulletin

Drug Intelligence Bulletin

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
What Drugs Should Labs Be Testing For In The Age Of Novel Psychoactive Substances?
Copy link
Facebook
Email
Notes
More

What Drugs Should Labs Be Testing For In The Age Of Novel Psychoactive Substances?

Keith Graves's avatar
Keith Graves
Jun 13, 2023
∙ Paid
5

Share this post

Drug Intelligence Bulletin
Drug Intelligence Bulletin
What Drugs Should Labs Be Testing For In The Age Of Novel Psychoactive Substances?
Copy link
Facebook
Email
Notes
More
Share

Novel Psychoactive Substances (NPS) present a formidable challenge to scientists, police officers, and those in public health alike. The landscape of these substances is continually shifting, with an average of two new drugs coming to market each week. This post seeks to provide insight into the current state of NPS and offer guidance on the drugs laboratories should prioritize for testing. It's particularly important for law enforcement officers to be cognizant of this evolving list, as it directly affects toxicological requests in various cases such as homicides, overdoses, and DUIs.


Drug Intelligence Bulletin is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.


Navigating the Evolving Landscape of NPS

The rapid introduction of new and varied NPS puts immense pressure on laboratories to stay informed and adapt their testing methodologies accordingly. NPS data is often region-specific and may quickly become outdated, complicating the prioritization process for labs. However, through extensive collaborations and initiatives, CFSRE’s NPS Discovery and the SOFT NPS Committee have compiled a set of recommendations to guide labs in their testing efforts.

image

Take DAR Now!

Testing Recommendations Based on Current Trends

These recommendations categorize NPS into three tiers based on the current trends and intelligence. They also suggest cut-off concentrations or reporting limits for each drug. Note that these values, given in ng/ml, are based on currently available quantitative data and comparisons with structurally similar NPS within the same subclass.

The drug recommendations are as follows:

TIER ONE (STRONGLY RECOMMEND)

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Graves and Associates INC
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More